CD38靶向[89Zr]Zr-DFO-达雷妥尤单抗用于多发性骨髓瘤成像的临床前开发
本研究在体外及多发性骨髓瘤(MM)小鼠模型中评价了CD38靶向的[89Zr]Zr-DFO-达雷妥尤单抗PET/CT成像。结果显示该探针对CD38+骨髓瘤细胞结合特异性好,可检出不同大小的CD38+肿瘤及髓内病灶,给药后7天肿瘤摄取明显。
要点
- [89Zr]Zr-DFO-达雷妥尤单抗对CD38+ MM1.S细胞结合特异性高,对CD38低表达细胞结合显著低。
- PET可检出8.5–128 mm³的CD38+骨髓瘤肿瘤,标准化摄取值范围为2.1–9.3。
- 给药后7天肿瘤摄取为27.7 ± 7.6 %ID/g,200倍过量未标记达雷妥尤单抗可实现体内阻断。
核心结论
- [89Zr]Zr-DFO-和Cy5-达雷妥尤单抗与CD38+人MM细胞结合极好,与CD38低表达细胞结合显著低。
- 达雷妥尤单抗生物偶联物正被评估用于治疗性放射性核素的影像引导递送。
研究设计与样本
- 临床前研究:将达雷妥尤单抗与DFO-Bz-NCS偶联后以89Zr标记,并用Cy5染料偶联达雷妥尤单抗进行细胞显微镜检查。
- 体外及体内评价使用CD38+人骨髓瘤MM1.S-萤光素酶(MM1.S)细胞;5TGM1-萤光素酶(5TGM1)/KaLwRij MM小鼠模型作为成像背景噪声对照。
- 在荷实体瘤和播散性MM肿瘤的重度联合免疫缺陷小鼠中进行[89Zr]Zr-DFO-达雷妥尤单抗PET/CT小动物成像。
- 在野生型和MM1.S荷瘤小鼠中于示踪剂给药后7天进行组织生物分布(1.11 MBq/只,每组n=4–6)。
主要发现
- [89Zr]Zr-达雷妥尤单抗-DFO可重复获得55.5 MBq/nmol(0.37 MBq/μg)的比活度。
- 流式细胞术证实MM1.S细胞表面CD38表达>99%;达雷妥尤单抗-Cy5共聚焦显微镜显示特异性细胞结合。
- 饱和结合试验得到解离常数3.3 nM(±0.58),受体密度10.1 fmol/mg(±0.64)。
- [89Zr]Zr-DFO-达雷妥尤单抗PET对检出大小8.5–128 mm³的CD38+骨髓瘤肿瘤具有特异性和敏感性,标准化摄取值范围为2.1–9.3。
- 生物发光图像证实的离散髓内病灶可被[89Zr]Zr-DFO-达雷妥尤单抗PET有效成像。
关键数值与推荐
- MM1.S细胞表面CD38表达>99%(流式细胞术)。
- 解离常数3.3 nM(±0.58),受体密度10.1 fmol/mg(±0.64)。
- 肿瘤大小8.5–128 mm³,标准化摄取值2.1–9.3。
- 给药后7天肿瘤摄取27.7 ± 7.6 %ID/g。
- 比活度55.5 MBq/nmol(0.37 MBq/μg)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a plasma B-cell hematologic cancer that causes significant skeletal morbidity. Despite improvements in survival, heterogeneity in response remains a major challenge in MM. Cluster of differentiation 38 (CD38) is a type II transmembrane glycoprotein overexpressed in myeloma cells and is implicated in MM cell signaling. Daratumumab is a U.S. Food and Drug Administration-approved high-affinity monoclonal antibody targeting CD38 that is clinically benefiting refractory MM patients. Here, we evaluated [89Zr]Zr-desferrioxamine (DFO)-daratumumab PET/CT imaging in MM tumor models. Methods: Daratumumab was conjugated to DFO-p-benzyl-isothiocyanate (DFO-Bz-NCS) for radiolabeling with 89Zr. Chelator conjugation was confirmed by electrospray ionization-mass spectrometry, and radiolabeling was monitored by instant thin-layer chromatography. Daratumumab was conjugated to Cyanine5 (Cy5) dye for cell microscopy. In vitro and in vivo evaluation of [89Zr]Zr-DFO-daratumumab was performed using CD38+ human myeloma MM1.S-luciferase (MM1.S) cells. Cellular studies determined the affinity, immunoreactivity, and specificity of [89Zr]Zr-DFO-daratumumab. A 5TGM1-luciferase (5TGM1)/KaLwRij MM mouse model served as control for imaging background noise. [89Zr]Zr-DFO-daratumumab PET/CT small-animal imaging was performed in severe combined immunodeficient mice bearing solid and disseminated MM tumors. Tissue biodistribution (7 d after tracer administration, 1.11 MBq/animal, n = 4-6/group) was performed in wild-type and MM1.S tumor-bearing mice. Results: A specific activity of 55.5 MBq/nmol (0.37 MBq/μg) was reproducibly obtained with [89Zr]Zr-daratumumab-DFO. Flow cytometry confirmed CD38 expression (>99%) on the surface of MM1.S cells. Confocal microscopy with daratumumab-Cy5 demonstrated specific cell binding. Dissociation constant, 3.3 nM (±0.58), and receptor density, 10.1 fmol/mg (±0.64), was obtained with a saturation binding assay. [89Zr]Zr-DFO-daratumumab/PET demonstrated specificity and sensitivity for detecting CD38+ myeloma tumors of variable sizes (8.5-128 mm3) with standardized uptake values ranging from 2.1 to 9.3. Discrete medullar lesions, confirmed by bioluminescence images, were efficiently imaged with [89Zr]Zr-DFO-daratumumab/PET. Biodistribution at 7 d after administration of [89Zr]Zr-DFO-daratumumab showed prominent tumor uptake (27.7 ± 7.6 percentage injected dose per gram). In vivo blocking was achieved with a 200-fold excess of unlabeled daratumumab. Conclusion: [89Zr]Zr-DFO- and Cy5-daratumumab demonstrated superb binding to CD38+ human MM cells and significantly low binding to CD38low cells. Daratumumab bioconjugates are being evaluated for image-guided delivery of therapeutic radionuclides.
引用
- Ghai A, Maji D, Cho N, et al. Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma. J Nucl Med. 2017. PMID: 29025987. doi:10.2967/jnumed.117.196063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。